Skip to main content
TipRanks
Go Ultimate75% OFF

Oncotelic Therapeutics (OTLC) AI Stock Analysis

86 Followers
OTLC

Oncotelic Therapeutics

(Other OTC:OTLC)

Select Model
Rating:43Neutral
Price Target:$0.01â–²(8.33% Upside)
Action:reiterated
Date:11/20/26

The overall score of 43 is heavily weighed down by Oncotelic Therapeutics' precarious financial position, chronic cash burn, and a severe technical downtrend typical of distressed early-stage biotechs. While its lack of profitability and plunging chart pose substantial risks to investors, recent forward-looking developments in its AI-driven oncology discovery platforms provide a modest fundamental bright spot in a largely speculative profile.

Positive Factors
Moderate reported leverageReported debt relative to equity is moderate, which could preserve financial flexibility for research investment and limit leverage-related pressure over the next several months. However, the reported scale changes reduce confidence in the comparability of this otherwise favorable balance-sheet signal.
Negative Factors
Minimal revenue and persistent operating lossesThe company has not established a stable commercial revenue base, while operating losses continue despite ongoing development activity. Minimal sales limit internal funding capacity and leave future progress dependent on achieving meaningful product or partnership economics.

Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%OTLC-87.37%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.90M
Dividend Yield
―
Average Volume (3M)
392.56K
Price to Earnings (P/E)
0.0
Beta (1Y)
0.09
Revenue Growth
―
EPS Growth
―
Country
US
Employees
41
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Oncotelic Therapeutics Business Overview & Revenue Model

Company Description

Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound desig...

Oncotelic Therapeutics Financial Statement Overview

Summary

Oncotelic Therapeutics exhibits a highly precarious financial profile with negligible revenue, persistent operating losses, and severely distressed cash flows. Despite maintaining a conservative debt-to-equity ratio of 0.06, extreme net income volatility driven by non-operating items and a negative ROE underscore the highly speculative, high-risk nature of its operations.

Income Statement

15Very Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Dec 2023Mar 2023Mar 2022
Income Statement
Total Revenue250.00K0070.00K00
Gross Profit250.00K0070.00K-12.84K-61.51K
EBITDA360.93M361.46M-3.80M-6.86M-5.60M-9.06M
Net Income247.43M249.28M-4.52B-7.90M17.82M-11.39M
Balance Sheet
Total Assets393.81T393.09M26.68M30.01M36.12M23.61M
Cash, Cash Equivalents and Short-Term Investments63.80B88.86K86.13K170.41K241.45K568.77K
Total Debt16.60T13.91M13.09M12.57M11.26M8.99M
Total Liabilities131.52T131.36M19.20M18.40M16.92M15.45M
Stockholders Equity263.47T262.76M8.25M12.13M19.41M7.96M
Cash Flow
Free Cash Flow-776.66B-1.38M-740.27K-1.32M-1.45M-4.43M
Operating Cash Flow-776.66B-1.38M-740.27K-1.32M-1.45M-4.43M
Investing Cash Flow000000
Financing Cash Flow1.21M1.39M656.00K1.25M1.13M4.53M

Oncotelic Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.01

Price Trends

50DMA0.02Negative
100DMA0.03Negative
200DMA0.04Negative

Market Momentum

MACD-0.00Positive
RSI34.70Neutral
STOCH-12.50Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 34.70 is Neutral, neither overbought nor oversold. The STOCH value of -12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLC.

Oncotelic Therapeutics Risk Analysis

Oncotelic Therapeutics disclosed 38 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.A material amount of our assets represents intangible assets, and our net income would be reduced if our intangible assets became impaired.Q4, 2023

Oncotelic Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

OTLC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ELUTELUT51Neutral$35.96M0.70267.71%―-52.81%7.54%
GRCEGRCE45Neutral$36.39M-1.33-38.33%――-110.40%
MAIAMAIA44Neutral$70.40M-2.29-153.44%――35.05%
OTLCOTLC43Neutral$5.99M0.00<0.01%―――
LTRNLTRN40Underperform$4.51M-0.21-674.37%――32.93%
CALCCALC39Underperform$8.07M-0.28-3029.57%――45.29%

* Healthcare Sector Average

Performance Comparison

0%100%OTLCGRCELTRNCALCELUTMAIADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
OTLC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
OTLCOncotelic Therapeutics Inc0.01-0.08-86.52%
GRCEGrace Therapeutics, Inc.1.71-1.40-45.02%
LTRNLantern Pharma, Inc.0.24-3.13-92.73%
CALCCalcimedica, Inc.1.26-19.69-93.99%
ELUTElutia Inc.0.900.3050.25%
MAIAMAIA Biotechnology, Inc.1.110.1212.12%

Oncotelic Therapeutics Corporate Events

Business Operations and Strategy

Oncotelic showcases AI-driven oncology discovery framework

Positive
Oct 26, 2026

On October 22, 2026, Oncotelic Therapeutics Chief Business Officer Saran Saund presented the company’s Partitioned Literature Aggregation framework at the 22nd Drug Discovery Strategic Summit in Millbrae, California. The talk detailed how partitionin...

Business Operations and StrategyProduct-Related Announcements

Oncotelic highlights PDAOAI platform and BIO REBOOT initiative

Positive
Oct 13, 2026

On October 7 and 8, 2026, Oncotelic Therapeutics representatives presented new technical details of their PDAOAI data-analytics platform and hepatocellular carcinoma research at the Drug Discovery 2026 conference in Burlingame, California. The platfo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026